Crystalline HER2 Inhibitor Forms for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for novel anti-HER2 monotherapies and dual therapies that effectively target both HER2 and HER2 mutants to treat HER2-driven cancers, which exhibit robust activity and overcome treatment resistance.
Innovation Solution
A solid form of (E)-1-(4-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)piperidin-1-yl)-3-(dimethylamino)prop-2-en-1-one, specifically in crystalline form, is developed for treating HER2-driven cancers, characterized by distinct X-ray powder diffraction reflections and thermal properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If trastuzumab and other HER2-targeted therapies are used to treat HER2-positive cancers, then treatment benefits are achieved, but treatment resistance develops over time
Solution Approach 1:
The patent segments the treatment approach by combining multiple HER2-targeting agents (trastuzumab, pertuzumab, and small molecule inhibitors like tucatinib) that target different aspects of HER2 signaling. This multi-pronged segmentation prevents resistance development by attacking the disease through multiple pathways simultaneously, ensuring sustained treatment effectiveness over time.
Solution Approach 2:
The patent employs composite therapy regimens that combine monoclonal antibodies (trastuzumab, pertuzumab) with small molecule tyrosine kinase inhibitors (tucatinib, neratinib). This composite approach creates synergistic effects where different mechanism-of-action agents work together to overcome resistance, extending durable response duration while maintaining treatment reliability.
2Reliability
If HER2-targeted therapies are combined to address resistance, then treatment outcomes improve, but treatment complexity increases
Solution Approach 1:
The patent utilizes monoclonal antibodies like trastuzumab and pertuzumab that serve multiple functions: they block HER2 signaling, induce antibody-dependent cellular cytotoxicity (ADCC), and modulate the tumor microenvironment. This multi-functionality allows single agents to address multiple resistance mechanisms, simplifying the overall treatment approach while maintaining improved outcomes.
Solution Approach 2:
The patent employs HER2-targeted therapies as intermediaries that mediate between the administered drug and the HER2-overexpressing tumor cells. These agents serve as selective mediators that specifically target HER2-positive cells while sparing normal cells, enabling effective combination therapy with reduced off-target toxicity despite increased regimen complexity.
3Reliability
If solid crystalline forms of HER2 inhibitors are developed, then drug stability and bioavailability are improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs parameter changes in the crystallization process, including controlling temperature, solvent composition, pH, and cooling rates to obtain specific crystalline forms of HER2 inhibitors. By optimizing these parameters, the patent achieves stable, bioavailable crystalline products while maintaining manufacturing feasibility through well-established crystallization techniques.
Solution Approach 2:
The patent utilizes phase transitions during the development of solid crystalline forms, including solvent evaporation, cooling crystallization, and polymorphic transitions. These controlled phase transitions enable the formation of stable crystalline structures from solution or melt, improving drug stability and bioavailability while using standard pharmaceutical manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline form of the compound demonstrates effective treatment of HER2-driven cancers with potential synergistic effects when combined with HER2-targeted therapies, enhancing treatment outcomes and overcoming resistance.
Implementation Method 1
characterized by distinct X-ray powder diffraction reflections and thermal properties
Data Source
AI summary
Provided are solid state forms of (E)-1-(4-(4-((4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)piperidin-1-yl)-4-(dimethylamino)but-2-en-1-one and salts thereof. Such solid state forms re useful in preparation of pharmaceutical compositions for the treatment of diseases.